![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » FDA Approves First Cannabis-Based Drug for Treating Epileptic Seizures
FDA Approves First Cannabis-Based Drug for Treating Epileptic Seizures
![Red_Approved_Stamp.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/Red_Approved_Stamp.gif?t=1578447203&width=430)
June 26, 2018
The FDA approved Epidiolex (cannabidiol) for treating seizures associated with two rare and severe forms of epilepsy, marking the country’s first agency approval of a cannabis-based drug.
Epidiolex is also the first FDA approved drug for treating patients with Dravet syndrome, a rare genetic condition that typically appears during the first year of life and causes prolonged and frequent seizures, as well as developmental issues in the patient.
“This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies,” said FDA Commissioner Scott Gottlieb.
Upcoming Events
-
21Oct